Cemiplimab-Associated Sinusoidal Obstruction Syndrome
- PMID: 37091208
- PMCID: PMC10118369
- DOI: 10.14309/crj.0000000000001038
Cemiplimab-Associated Sinusoidal Obstruction Syndrome
Abstract
A 58-year-old woman developed new-onset recurrent ascites after the recent initiation of cemiplimab for the treatment of advanced basal cell carcinoma. A comprehensive serological workup for viral, metabolic, and autoimmune causes was unrevealing. Transjugular liver biopsy demonstrated parenchymal changes consistent with a diagnosis of sinusoidal obstruction syndrome. While this is a condition commonly observed in patients after hematopoietic stem cell transplantation or use of chemotherapeutic agents, it should also be considered in patients who develop new-onset liver dysfunction after the initiation of checkpoint inhibitors.
Keywords: cemiplimab; check-point inhibitor; nodular regenerative hyperplasia; sinusoidal obstruction syndrome; veno-occlusive disease.
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Figures




References
-
- DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venoocclusive disease. Hepatology. 1996;23(3):589–99. - PubMed
-
- Fuste B, Escolar G, Marin P, Mazzara R, Ordinas A, Diaz-Ricart M. G-CSF increases the expression of VCAM-1 on stromal cells promoting the adhesion of CD34+ hematopoietic cells: Studies under flow conditions. Exp Hematol. 2004;32(8):765–72. - PubMed
-
- Mercanoglu F, Turkmen A, Kocaman O, et al. . Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. Transpl Proc. 2004;36(5):1357–60. - PubMed
-
- Zoja C, Furci L, Ghilardi F, Zilio P, Benigni A, Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986;55(4):455–62. - PubMed
Publication types
LinkOut - more resources
Full Text Sources